stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) EBITDA
Neurocrine Biosciences, Inc.'s EBITDA for fiscal 2025 was $636.5M, up 11.4% from $571.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $976.5M. Over the past ten years it has ranged from −$142.4M (fiscal 2016) to $636.5M (fiscal 2025) — the current reading is the highest in ten years. Neurocrine Biosciences, Inc. ranks 7th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $636.5M | 11.39% |
| FY2024 | $571.4M | 125.05% |
| FY2023 | $253.9M | (5.37%) |
| FY2022 | $268.3M | 94.28% |
| FY2021 | $138.1M | (28.45%) |
| FY2020 | $193.0M | 93.00% |
| FY2019 | $100.0M | 67.50% |
| FY2018 | $59.7M | — |
| FY2017 | −$115.4M | — |
| FY2016 | −$142.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $380.1M | 111.99% |
| Jun 2026 | $179.3M | (10.66%) |
| Mar 2026 | $200.7M | (7.26%) |
| Dec 2025 | $216.4M | (8.30%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.3B |
| ZTS Zoetis Inc. compare | $4.0B |
| VTRS Viatris Inc. compare | $2.7B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. | $976.5M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| ALKS Alkermes plc compare | $217.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement